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Abstract
Objective: Adrenal vein sampling (AVS) represents the current diagnostic standard for subtype differentiation in 
primary aldosteronism (PA). However, AVS has its drawbacks. It is invasive, expensive, requires an experienced 
interventional radiologist and comes with radiation exposure. However, exact radiation exposure of patients 
undergoing AVS has never been examined.
Design and methods: We retrospectively analyzed radiation exposure of 656 AVS performed between 1999 and 
2017 at four university hospitals. The primary outcomes were dose area product (DAP) and fluoroscopy time (FT). 
Consecutively the effective dose (ED) was approximately calculated.
Results: Median DAP was found to be 32.5 Gy*cm2 (0.3–3181) and FT 18 min (0.3–184). The calculated ED was 
6.4 mSv (0.1–636). Remarkably, values between participating centers highly varied: Median DAP ranged from 16 to 
147 Gy*cm2, FT from 16 to 27 min, and ED from 3.2 to 29 mSv. As main reason for this variation, differences regarding 
AVS protocols between centers could be identified, such as number of sampling locations, frames per second and the 
use of digital subtraction angiographies.
Conclusion: This first systematic assessment of radiation exposure in AVS not only shows fairly high values for patients, 
but also states notable differences among the centers. Thus, we not only recommend taking into account the risk 
of radiation exposure, when referring patients to undergo AVS, but also to establish improved standard operating 
procedures to prevent unnecessary radiation exposure.
Introduction
Primary aldosteronism (PA) is the most common curable 
cause of secondary hypertension and characterized by the 
autonomous adrenocortical oversecretion of aldosterone 
leading to cardiovascular and metabolic complications 
(1, 2, 3, 4, 5). Most commonly, the aldosterone excess 
either results from bilateral adrenal hyperplasia (BAH) or 
from a unilateral aldosterone-producing adenoma (APA) 
(6). Correct distinction between unilateral or bilateral 
disease is of high importance due to different therapeutic 
approaches: whereas PA due to APA may be cured by 
adrenalectomy, patients with BAH receive life-long 
treatment with mineralocorticoid receptor antagonists 
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(7). AVS is currently recommended as standard diagnostic 
tool for subtype differentiation in PA (2). However, 
AVS has its drawbacks: It is an invasive and expensive 
procedure with poor standardization regarding sampling 
protocols and interpretation of results among centers (8, 
9, 10). Success rates and complications such as adrenal 
hemorrhage also differ depending on the experience of 
the interventionalist (11, 12). Furthermore, there is not 
only an ongoing debate regarding the use of AVS itself (13, 
14, 15), but also its superiority in comparison to adrenal 
CT scan in terms of clinical outcome (9, 16). However, 
the SPARTACUS-trial raised controversial discussions itself 
due to its study design and patient selection (15, 17). The 
clinical usefulness of more recent approaches to replace 
AVS by molecular imaging is yet to be defined within 
clinical trials (18, 19).
Another argument brought forward against AVS is 
the potentially high radiation dose, to which patients 
are submitted during the procedure. Even though there 
are proven risks linked to radiation exposure, e.g. an 
increased incidence of cancer, to our knowledge, there is 
no available data so far addressing this particular problem. 
We, therefore, aimed to retrospectively analyze radiation 
exposure of AVS in four different specialized centers across 
Germany.
Patients and methods
Patients
We performed a retrospective analysis to assess radiation 
exposure caused by AVS. In all patients, informed consent 
for performance of AVS within clinical routine had been 
obtained in accordance with respective local regulations. 
The analysis was approved by the Ethics Committee of 
the University of Würzburg (AZ121/17). Overall, 658 AVS 
performed between 1999 and 2017 in Berlin (center 1, 
n = 53), Leipzig (center 2, n = 52), Munich (center 3, n = 400) 
and Würzburg (center 4, n = 151) with documented 
information regarding dose area product (DAP, Gy*cm2), 
fluoroscopy time (FT, min) and, if available, performing 
radiologist and success of cannulation based on cortisol 
measurements were included in the analysis, without 
specific exclusion criteria. We furthermore collected 
information on sampling locations and imaging 
modalities for each center. Data were obtained at each 
participating center and sent to the coordinating center 
after anonymization.
Assessment of radiation exposure
Assessed radiation measures were FT (min), DAP (Gy*cm2) 
and effective dose (ED, mSv). FT constitutes for the amount 
of time during the procedure, in which fluoroscopy is 
used. It poorly correlates with other dose indicators. 
DAP is defined as the product of the radiation dose to air 
multiplied by the area of X-ray field, as measured by an 
ionization chamber mounted on the X-ray collimator. 
DAP is used to assess the radiation exposure of irrigated 
tissues and forms the basis for calculation of ED. ED 
represents the stochastic risk related to ionizing radiation 
and was approximately estimated as previously described: 
ED (mSv) = DAP (Gy*cm²) × 0.2 (mSv/Gy*cm²) (20).
Across participating sites the following angiography 
systems were used: Artis Zee, Axiom Artis XA C, Axiom 
Artis BA, Multistar TOP, Polystar XA (each Siemens 
Healthcare), Innova 4100 (GE Healthcare) and ALLURA 
Xper FD System (Philips Healthcare). For details, see 
Table 1.
Statistical analysis
Comparison of not normally distributed continuous data 
was performed using Mann–Whitney U test. Normally 
distributed data are given as mean ± s.d., whereas not 
normally distributed parameters are shown as median 
(min–max). Kruskal–Wallis test and post hoc analysis 
(Dunn–Bonferroni) were used to compare DAP and FT 
grouped by number of performed AVS. P value <0.05 
was considered statistically significant. SPSS version 24.0 
(IBM) was used for statistical analysis.
Results
General characteristics of AVS
Overall, 658 procedures were assessed. Due to missing 
data for ED, DAP and FT, two patients were excluded from 
the study (n = 656). Median age of patients was 53 (16–
85) years. Ten patients underwent AVS twice. Two centers 
(center 3, n = 400/400; center 4, n = 81/151) used rapid 
cortisol measurements during AVS to determine correct 
catheter localization. At center 3, bilateral simultaneous 
catheterization of adrenal veins was carried out in 35% of 
cases, whereas all other AVS procedures were performed 
as sequential catheterization. All AVS were performed 
without cosyntropin stimulation. Cannulation was 
successful in 80% of AVS with a large variability across 
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participating centers Table  2. Success rate of AVS was 
significantly higher when cortisol measurements were 
performed during AVS (89 vs 56%, P < 0.001).
DAP, ED and fluoroscopy time
Median DAP across all centers was at 33 Gy*cm2 (0.3–
3181). However, DAP showed high variation among 
institutions but also within the respective centers, ranging 
from 16.2 Gy*cm2 (0.3–3181) up to 147 Gy*cm2 (1.1–
1186) Table  3. Especially DAP values recorded at center 
3 were significantly lower compared to center 1, 2 and 4 
respectively (all P < 0.001) Fig. 1. Calculated ED measured 
6.5 mSv (0.05–636), again displaying a high variability 
within and across the centers Table  3. Ten patients 
underwent AVS twice, leading to a median cumulative ED 
of 36 mSv (0.92–113.95). Overall, FT was 18 min (0.3–184). 
FT varied from 16 min (0.3–184) at center 3 up to 27 min 
(4.0–116) at center 4 (3 vs 4 P ≤ 0.001). Table  3 + Fig.  1. 
Furthermore, radiation exposure significantly increased 
with age. Whereas for example patients ≤40 years (n = 78) 
received a median ED of 3.4 mSv (0.1–237), patients 
>70  years (n = 44) were exposed to 15 mSv (1.2–178) 
(P < 0.001). Additionally, median ED was significantly 
lower in female patients (8.9 vs 4.0 mSv, P < 0.001).
Regarding experience level of performing radiologists, 
radiation exposure decreased with increasing numbers of 
performed procedures Fig. 2.
DAP, ED and FT were also significantly lower in 
successful AVS (FTsuccessful cannulation = 16 min (0.3–184), 
FTunsuccessful cannulation = 28 min (4.4–116), DAPsuccessful cannulation = 
25 Gy*cm2 (0.3–3181), DAPunsuccessful cannulation = 80 Gy*cm
2 
(1.1–1186), EDsuccessful cannulation = 5.0 mSv (0.1–636), 
EDunsuccessful cannulation = 16 mSv (0.2–237), all P < 0,001). Over 
the period of 18 years, there were significant differences 
in DAP, ED and FT with predominantly consistent values 
in more recent years. Fig. 3. At center 3 DAP, ED and FT 
were significantly higher in cases of bilateral simultaneous 
catheterization compared to AVS with sequential 
catheterization of adrenal veins (DAPsimultaneous = 27 Gy*cm
2 
(0.3–3181), DAPsequential = 14 Gy*cm
2 (0.8–423), P < 0.001; 
EDsimultaneous = 5.4 mSv (0.1–636), EDsequential = 2.8 mSv 
(0.2–85), P < 0.001; FTsimultaneous = 18 min (0.3–184), 
FTsequential = 14 min (1.9–104), P = 0.001).
Table 1 Overview of imaging modalities.
Center Angiography system
Sampling locations number 
(location) DSA number (location) Frames per second
1 ALLURA Xper FD System 6 (LAV, RAV, 2xLRV, 2xVCI) 3* (2xRAV, LAV) 2
2 Innova 4100 Axiom Artis BA 6 (LAV, RAV, 2xVCI, RRV, LRV) 2* (LAV, RAV) 15
3 Multistar TOP
Artis Zee MP
Axiom Artis XA C
Polystar XA
3 (LAV, RAV, LFV or RFV) 0 7.5
4 Artis Zee MP 6 (LAV, RAV, VCI, VCS, RRV, LRV) 6 (LAV, RAV, VCI, VCS, RRV, LRV) 7.5
*In case of unclear anatomy, additional DSA was performed.
DSA, digital subtraction angiography; LAV, left adrenal vein; LFV, left femoral vein; LRV, left renal vein; RAV, right adrenal vein; RFV, right femoral vein; 
RRV, right renal vein; VCI, Vena cava inferior; VCS, Vena cava superior.
Table 2 General characteristics on age, sex, rapid cortisol measurements and success of cannulation. Data are presented as % 
(n) or as mean±S.D.
Center Age, mean ± s.d. Females Males 
Cortisol 
measurement
Bilateral 
simultaneous 
catheterization % (n)
Cosyntropin 
stimulation
 
 
Successful cannulation % (n)
1 (n = 53) 49 ± 12 45 (24) 55 (29) No No No 59 (31)
2 (n = 52) 55 ± 12 58 (30) 42 (22) No No No 61 (31)
3 (n = 400) 52 ± 11 64 (256) 36 (144) Yes Yes; M: 35 (138) No 90 (361)
4 (n = 151) 57 ± 11 38 (57) 62 (94) Yes No No F: 50 (35/70)*; M: 82 (66/81)**
Total 53 ± 11 56 (367) 44 (289) 80 (524)
Center 2: n = 52 (n = 51 for successful cannulation).
*AVS without rapid cortisol measurement; **AVS with rapid cortisol measurement.
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Sampling locations and imaging modalities
Number of standard sampling locations varied between 
three (center 3) and six (centers 1, 2 and 4) (Details see 
Table  1). Digital subtraction angiography (DSA) was 
performed regularly in three centers (centers 1, 2 and 
4) for two, three or all six locations, as well as in cases 
of unclear anatomy of the adrenal veins. In contrast, 
sampling locations in center 3 were documented just by 
using last image hold, but not an additional DSA. The 
number of frames per second ranged between 7.5 and 
15. All centers used low-dose protocols implemented in 
respective X-ray system and reduced field of view to the 
necessary minimum. An overview of different imaging 
modalities is presented in Table 1.
Discussion
In this study, we demonstrate that AVS is associated 
with a relevant exposure to radiation in some but not 
all centers who participated in this study. Even though 
overall ED measured 6.5 mSv, this was highly variable 
across participating centers and respective patients 
(0.1–636 mSv). Highest median ED for one center was at 
29 mSv, a value equivalent to 1470 chest X-rays (21) and 12 
times the natural background radiation of approximately 
2.4 mSv per year (22). For further reference, abdominal 
CT alone, routinely performed in patients with PA to 
assess the presence of nodules and for visualization of 
adrenal veins prior to AVS, is associated with an ED of 
approximately 10 mSv (23).
It is well known that there are certain risks linked 
to radiation exposure, such as skin reactions, DNA 
damage and ultimately cancer induction (24). Whereas 
skin lesions and cataract are regarded as predictable 
deterministic effects occurring above a threshold 
radiation dose estimated at 500 mSv (25), cancer 
induction represents a stochastic risk, making it nearly 
impossible to determine radiation as the specific cause 
of cancer in single patients, especially due to the long 
latency period between radiation exposure and clinical 
manifestations. Data available on malignancies in PA 
showed a lifetime malignancy occurrence of 9.6% in 
PA patients compared to 6.0% of hypertensive controls 
which, however, did not reach statistical significance 
(P = 0.08) (26). However, several diagnoses of malignancy 
had been made prior any AVS in this cohort (26) and 
long-term data on malignancy occurrence after AVS are 
so far missing.
Another main result of this study is the difference 
in radiation doses between participating institutions, 
Table 3 Dose area product, effective dose and fluoroscopy 
time across participating centers. Values are displayed as 
median (min–max).
Center DAP (Gy*cm2) ED (mSv) FT (min)
1 147 (1.1–1186) 29 (0.2–237) 22 (5.3–40)
2 48 (10.0–610) 9.6 (2.0–122) 20 (0.8–50)
3 16 (0.3–3181) 3.2 (0.1–636) 16 (0.3–184)
4 144 (8.2–1166) 29 (1.6–233) 27 (4.0–116)
DAP, dose area product (Gy*cm2); ED, effective dose (mSv); FT, 
fluoroscopy time (min).
Figure 1
Dose area product (DAP, Gy*cm2) and fluoroscopy time  
(FT, min) in participating centers. (A) DAP, 1 vs 3 P < 0.001, 2 vs 
3 P < 0.001, 3 vs 4 P < 0.001, (B) FT, 1 vs 4 P = 0.001, 2 vs 4 
P = 0.002, 3 vs 4 P < 0.001. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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which can be explained by the respective variation of 
imaging modalities. In contrast to all other centers, 
center 3 performed less samplings in fewer locations and, 
most importantly, did not use DSA for visualization of 
vascular structures at any point, but instead documented 
catheterization of adrenal veins by dynamic fluoroscopic 
sequences or using last image hold, allowing for the last 
image to be saved and displayed on the monitor after 
stopping fluoroscopy. The use of DSA causes approximately 
ten times higher radiation doses compared to fluoroscopic 
sequences, therefore being not only a plausible, but also 
an adjustable factor explaining differences in radiation 
exposure across participating centers. Furthermore, the 
use of 7.5, instead of 15 or even 30 frames per second, 
the patient’s distance from the X-ray tube and the 
detector, the correct use of collimators and the system 
settings used for performance of AVS account for more 
possible influencing parameters. Interestingly, bilateral 
Figure 2
Changes in dose area product (DAP, Gy*cm2) and fluoroscopy 
time (FT, min) over time depending on the number of AVS 
performed by a single radiologist at center 4 (n = 82). 
x-axis = number of AVS in groups of 20 (22) AVS. (A) DAP, 1–20: 
180 (52–461); 21–40: 80 (18–339); 41–60: 77 (17–291); 61–82: 61 
(8.2–315); 1–20 vs 21–40 P = 0.011; 1–20 vs 41–60 P = 0.008; 1–20 
vs 60–82 P = 0.013. (B) FT, 1–20: 25 (11–86); 21–40: 19 (9.1–55); 
41–60: 19 (6.0–45); 61–82: 19 (4.0–81). *P ≤ 0.05, **P ≤ 0.01.
Figure 3
Dose area product ((A), DAP, Gy*cm²) and fluoroscopy time 
((B), FT, min) across different years. <2009: n = 39, DAP 246 
(9.2–888), FT 28 (15–99); 2009/2010: n = 75, DAP 74 (1.1–705), 
FT 22 (2.6–116); 2011/2012: n = 119, DAP 22 (0.8–789), FT 16 
(0.8–104); 2013/2014: n = 177, DAP 18 (1.2–1167), FT 15 
(1.9–103); 2015/2016: n = 212, DAP 41 (0.3–3181), FT 19 
(0.3–184); 2017: n = 24, DAP 53 (2.5–222), FT 16 (4.0–63). 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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simultaneous catheterization was associated with a 
significant increase in radiation exposure.
Based on the results of this study, there is obvious 
room for improvement regarding technical performance 
of AVS. To minimize radiation exposure, we recommend 
adopting some adjustments to currently applied 
protocols in the future: Documentation of adrenal veins 
should be done using predominantly last image hold, 
therefore limiting DSA to a minimum. Additionally, it 
seems possible to reduce number of sample locations to 
both adrenal veins and the inferior vena cava without 
compromising the validity and quality of AVS results, also 
resulting in lower FT and DAP. The radiation field should 
be limited to the necessary minimum. These adjustments 
should not only be considered to reduce patient exposure, 
but also the operator dose, mainly caused and determined 
by patient scatter (27). Our data furthermore indicate 
that the experience of the investigator is of relevance. In 
addition, centers performing rapid cortisol measurements 
during AVS showed much higher success rates of >80% 
in comparison to those without application of this 
technique (28). Off note, this was not associated with 
higher EDs to the patients as similarly documented 
by a recent study (29). To avoid repeated AVS, it may 
therefore be postulated this procedure is performed in 
centers with sufficient volumes of investigations and that 
rapid cortisol measurement becomes standard, aiming 
at success rates comparable to available data (28, 29). In 
addition to implementing changes regarding execution of 
AVS, radiation exposure should generally be kept in mind, 
when making the decision to perform AVS, even more so 
in young patients.
There are some limitations to this study: Data on 
BMI of patients, a factor known to influence DAP, was 
not recorded (30). However, the vast differences observed 
between centers are unlikely to be caused predominantly by 
inhomogeneous distribution of BMI. Regarding variations 
in DAP, ED and FT between different years, data collection 
started at different time points at each center (1: 2008, 2: 
1999, 3: 2009, 4: 2005). The significantly higher DAP, ED 
and FT of AVS performed from 1999 to 2008 (n = 39) and 
in 2009 compared to the following years can be attributed 
both to improved results over time in two centers and 
mainly by the absence of data from center 3 (<2009: n = 0, 
2009: n = 2), therefore leading to higher values in general. 
However, it should be noted, that all participating centers 
were experienced in the performance of AVS.
In conclusion, this first systematic assessment shows 
that AVS may be associated with fairly high radiation 
exposure of patients with PA with significant differences 
across participating centers. We therefore not only suggest 
taking this risk into account when referring patients to 
undergo AVS, but also recommend the establishment and 
application of a common protocol to reduce and prevent 
unnecessary exposure to radiation.
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